Title |
Tapentadol Extended Release for Chronic Pain Patients
|
---|---|
Published in |
Advances in Therapy, January 2013
|
DOI | 10.1007/s12325-013-0002-y |
Pubmed ID | |
Authors |
Robert Taylor, Joseph V. Pergolizzi, Robert B. Raffa |
Abstract |
Chronic pain reduces quality of life, utilizes healthcare resources, and increases healthcare costs. It is widespread, but generally inadequately treated or managed, partly due to several obstacles, including a limited number of mechanistic options for long-term pharmacologic agents. Opioids are generally the primary class of analgesic prescribed, but because of associated side effects during long-term treatment, many patients become noncompliant or discontinue treatment. A long-term use analgesic with a good benefit/risk ratio is advantageous. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Australia | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Science communicators (journalists, bloggers, editors) | 1 | 50% |
Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 2% |
Italy | 1 | 2% |
Unknown | 59 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 15 | 25% |
Student > Master | 10 | 16% |
Student > Ph. D. Student | 4 | 7% |
Other | 4 | 7% |
Student > Postgraduate | 3 | 5% |
Other | 8 | 13% |
Unknown | 17 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 21 | 34% |
Nursing and Health Professions | 6 | 10% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
Psychology | 3 | 5% |
Agricultural and Biological Sciences | 2 | 3% |
Other | 7 | 11% |
Unknown | 19 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 April 2021.
All research outputs
#6,253,341
of 22,694,633 outputs
Outputs from Advances in Therapy
#542
of 2,332 outputs
Outputs of similar age
#73,980
of 306,282 outputs
Outputs of similar age from Advances in Therapy
#2
of 19 outputs
Altmetric has tracked 22,694,633 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 2,332 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 306,282 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.